參考資料
  1. Hong Kong Cancer Registry. Top Ten Cancers. Available at https://www3.ha.org.hk/cancereg/topten.html (Last accessed: 6 Jul 2020).
  2. Vasan N, et al. Ann Oncol. 2019;30(Suppl 10):x3-x11.
  3. The Cancer Genome Atlas Network. Nature. 2012;490:61-70.
  4. Hong Kong Breast Cancer Foundation. Hong Kong Breast Cancer Registry Report No. 12 (Issue 2020). Available at: https://www.hkbcf.org/en/our_research/main/519/ (Last accessed Nov 2020).
  5. Hong Kong Cancer Registry. Female Breast Cancer in 2018. Available at https://www3.ha.org.hk/cancereg/pdf/factsheet/2018/breast_2018.pdf (Last accessed: 31 Oct 2020).
  6. American Cancer Society. Breast Cancer Facts & Figures 2019-2020. Available at https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2019-2020.pdf (Last accessed: 6 Jul 2020).
  7. American Cancer Society. Breast Cancer Hormone Receptor Status. Available at https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-hormone-receptor-status.html (Last accessed: 6 Jul 2020).
  8. Prat, A., et al. Nat Rev Clin Oncol. 2008;5:531–542.
  9. American Cancer Society. Breast Cancer HER2 Status. Available at https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-her2-status.html (Last accessed: 6 Jul 2020).
  10. American Cancer Society. Triple-negative Breast Cancer. Available at https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/types-of-breast-cancer/triple-negative.html (Last accessed: 6 Jul 2020).
  11. Presti D, et al. Cancers (Basel). 2019;11(9):1242.
  12. Mosele F, et al. Ann Oncol. 2020;31(3):377-386.
  13. Whitman M, et al. Type I Phosphatidylinositol Kinase Makes a Novel Inositol Phospholipid, phosphatidylinositol-3-phosphate. Nature 1988;332:644-646.
  14. Samuels Y, Waldman T. Oncogenic Mutations of PIK3CA in Human Cancers. Curr Top Microbiol Immunol 2010;347:21-41.
  15. Sabine VS, Crozier C, Brookes CL, et al. Mutational analysis of PI3K/AKT signaling pathway in Tamoxifen Exemestane Adjuvant Multinational pathology study. J Clin Oncol. 2014;32(27):2951-2958.
  16. Miller TW, et al. J Clin Invest. 2010;120(7):2406-2413.
  17. Fitzgerald DM, et al. Ann Oncol. 2019;30(suppl_5):v104-v142.
  18. John Hopkins Medicine. Breast Biopsy. Available at https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/breast-biopsy (Last accessed: 6 Jul 2020).
  19. Sarnecka AK, Nawrat D, Piwowar M, Ligeza J, Swadzba J, Wojcik P. DNA extraction from FFPE tissue samples:a comparison of three procedures. Contemp Oncol (Pozn) 2019;23:52-8.
  20. Brandão M, Caparica R, Eiger D, de Azambuja E. Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors. Ann Oncol. 2019;30(Suppl_10):x27-x42.
  21. Tay TKY, Tan PH. Arch Pathol Lab Med. 2020 Feb 11. doi: 10.5858/arpa.2019-0559-RA. [Epub ahead of print].
  22. Mannelli C. Tissue vs Liquid Biopsies for Cancer Detection: Ethical Issues. J Bioeth Inq. 2019;16:551-7.
  23. Arneth B. Update on the types and usage of liquid biopsies in the clinical setting: a systematic review. BMC Cancer. 2018;18:527.
  24. NCCN. NCCN Guidelines Breast Cancer (Version 4.2020). Available at https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (Last accessed: 6 Jul 2020)
  25. Cardoso F, et al. Ann Oncol. 2020 Sep 23.
See What Lies Beneath 潛在真相